Search Results - "Gislum, Mette"

Social inequality and incidence of and survival from cancer in a population-based study in Denmark, 1994–2003: Background, aims, material and methods by Dalton, Susanne Oksbjerg, Steding-Jessen, Marianne, Gislum, Mette, Frederiksen, Kirsten, Engholm, Gerda, Schüz, Joachim

“…Abstract The purpose of this register-based study was to identify variations in cancer incidence and survival after cancer in Denmark on the basis of a range…”
Get full text

Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses by Pratley, Richard E., Crowley, Matthew J., Gislum, Mette, Hertz, Christin L., Jensen, Thomas B., Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B.

“…Introduction The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2…”
Get full text

Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case-control study by Grønbaek, Henning, Johnsen, Søren P, Jepsen, Peter, Gislum, Mette, Vilstrup, Hendrik, Tage-Jensen, Ulrik, Sørensen, Henrik T

“…Liver diseases are suspected risk factors for intracerebral haemorrhage (ICH). We conducted a population-based case-control study to examine risk of ICH among…”
Get full text

Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones by Wogelius, Pia, Nørgaard, Mette, Gislum, Mette, Pedersen, Lars, Schønheyder, Henrik C., Sørensen, Henrik Toft

“…In a database cohort study, the risk of adverse birth outcome in Danish women who redeemed a fluoroquinolone prescription during pregnancy was examined. Among…”
Get full text

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease by Rossing, Peter, Baeres, Florian M M, Bakris, George, Bosch-Traberg, Heidrun, Gislum, Mette, Gough, Stephen C L, Idorn, Thomas, Lawson, Jack, Mahaffey, Kenneth W, Mann, Johannes F E, Mersebach, Henriette, Perkovic, Vlado, Tuttle, Katherine, Pratley, Richard

“…ABSTRACT Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs)…”
Get full text

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study by Wang, Gang, Gislum, Mette, Filippov, Gleb, Montgomery, Stuart

“…Abstract Objective: This randomized, double-blind 8 week study compared the efficacy and tolerability of fixed-dose treatment with vortioxetine (10 mg/day) and…”
Get full text

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial by McGuire, Darren K., Busui, Rodica P., Deanfield, John, Inzucchi, Silvio E., Mann, Johannes F. E., Marx, Nikolaus, Mulvagh, Sharon L., Poulter, Neil, Engelmann, Mads D. M., Hovingh, G. Kees, Ripa, Maria Sejersten, Gislum, Mette, Brown‐Frandsen, Kirstine, Buse, John B.

“…Aim To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL) and the baseline clinical data of its participants. Materials and…”
Get full text

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA by Hakala, Mika, Gislum, Mette, Skuban, Aleksandar, Meehan, Stine

“…Abstract Background Long-term maintenance treatment is recommended to control the symptoms of schizophrenia1,2; therefore, safety monitoring for longer than…”
Get full text

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial by Yabe, Daisuke, Nakamura, Jiro, Kaneto, Hideaki, Deenadayalan, Srikanth, Navarria, Andrea, Gislum, Mette, Inagaki, Nobuya, Arisaka, T, Asakura, T, Azuma, N, Fukuda, S, Fukushima, Y, Harada, N, Inoue, S, Ishida, H, Ishii, H, Ishikawa, S, Jinnouchi, H, Kaneko, S, Kanno, K, Kato, M, Kato, Y, Kawada, T, Kim, H, Kiyosue, A, Matsuoka, O, Miho, O, Nakamoto, S, Nakamura, S, Nakanishi, S, Nishimura, H, Numata, A, Ohama, T, Okabe, T, Okuguchi, F, Osonoi, T, Sasaki, T, Seino, H, Shin, K, Shiraiwa, T, Sugiura, T, Wada, S, Yamauchi, A

“…New glucose-lowering medications need to be investigated in east Asian populations, as the clinical characteristics of type 2 diabetes differ between western…”
Get full text

Waterpipe Use Predicts Progression to Regular Cigarette Smoking Among Danish Youth by Jensen, Poul Dengsoe, Cortes, Rikke, Engholm, Gerda, Kremers, Stef, Gislum, Mette

“…Waterpipe smoking among Danish, Swedish, and German youth is increasing dramatically, indicating the emergence of a new health threat. This study assessed the…”
Get full text

Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Material and methods by Engholm, Gerda, Gislum, Mette, Bray, Freddie, Hakulinen, Timo

“…Comparable data on cancer incidence and mortality in Denmark, Finland, Iceland, Norway, and Sweden are available for analysis through a collaboration of the…”
Get more information

Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: A population-based nested case-control study by Larsen, Torben Bjerregaard, Sørensen, Henrik Toft, Gislum, Mette, Johnsen, Søren Paaske

“…Abstract Background Smoking and obesity are associated with adverse pregnancy outcomes. The aim of the present study was to examine the association between…”
Get full text

957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program by BUSE, JOHN B., CROWLEY, MATTHEW, ERIKSSON, JAN W., GISLUM, METTE, HERTZ, CHRISTIN L., KAISER, MARCEL, NIELSEN, ANNE MOELLER, HALUZIK, MARTIN

“…The global PIONEER program investigated the efficacy and safety of the first oral glucagon-like peptide-1 receptor agonist, oral semaglutide. Across PIONEER…”
Get full text

Oral Semaglutide Reduces HbA.sub.1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses by Pratley, Richard E, Crowley, Matthew J, Gislum, Mette, Hertz, Christin L, Jensen, Thomas B, Khunti, Kamlesh, Mosenzon, Ofri

“…Introduction The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2…”
Get full text

Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964-2003 followed up to the end of 2006 by Klint, Asa, Engholm, Gerda, Storm, Hans H, Tryggvadóttir, Laufey, Gislum, Mette, Hakulinen, Timo, Bray, Freddie

“…Cancers of the digestive organs (including the oesophagus, stomach, small intestine, colon, rectum and anus, liver, gallbladder, and pancreas) constitute…”
Get more information

Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006 by Klint, Asa, Tryggvadóttir, Laufey, Bray, Freddie, Gislum, Mette, Hakulinen, Timo, Storm, Hans H, Engholm, Gerda

“…Cancers of the female genital organs constitute more than 12% of all female cancers in the Nordic countries. The group includes cervix uteri, corpus uteri,…”
Get more information

Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations by Wogelius, Pia, Nørgaard, Mette, Gislum, Mette, Pedersen, Lars, Munk, Estrid, Mortensen, Preben Bo, Lipworth, Loren, Sørensen, Henrik Toft

“…Background: Human data on the teratogenicity of selective serotonin reuptake inhibitors (SSRIs) are limited. We examined the association between SSRI use…”
Get full text

Oral Semaglutide Reduces HbA 1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses by Pratley, Richard E, Crowley, Matthew J, Gislum, Mette, Hertz, Christin L, Jensen, Thomas B, Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B

“…The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D)…”
Get full text

58 - Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program by Ngui, Daniel, Buse, John, Crowley, Matthew, Eriksson, Jan W., Gislum, Mette, Hertz, Christin Løth, Kaiser, Marcel, Nielsen, Anne Møller, Haluzík, Martin

Get full text

Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964-2003 followed up to the end of 2006 by Tryggvadóttir, Laufey, Gislum, Mette, Hakulinen, Timo, Klint, Asa, Engholm, Gerda, Storm, Hans H, Bray, Freddie

“…A previous Nordic study showed a marked and steady increase in the age-adjusted 5-year relative survival of skin melanoma patients diagnosed during the period…”
Get more information